FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain

summarizeSummary

OKYO Pharma announced FDA authorization for a single-patient expanded access IND for urcosimod (0.05%) to treat severe neuropathic corneal pain, highlighting the drug's potential in an area with no approved therapies.

check_boxKey Events

• FDA Authorizes Compassionate Use

  The U.S. Food and Drug Administration (FDA) has authorized a single-patient expanded access (compassionate use) Investigational New Drug (IND) application for urcosimod (0.05%).

• Targets Neuropathic Corneal Pain

  Urcosimod will be used in a patient with severe neuropathic corneal pain (NCP) who has limited therapeutic options and no FDA-approved treatments available.

• Reinforces Development Pathway

  This authorization follows urcosimod receiving the first IND to treat NCP and Fast Track designation, with a 120-patient Phase 2b/3 multiple-dose study expected to initiate this year.

auto_awesomeAnalysis

This FDA authorization for compassionate use, while for a single patient, is a positive regulatory development for OKYO Pharma's lead candidate, urcosimod. It underscores the significant unmet medical need in neuropathic corneal pain and provides an opportunity to gather additional real-world data for the drug. For a clinical-stage biopharmaceutical company, such authorizations can build confidence in the drug's profile and the company's commitment to addressing severe conditions, potentially supporting ongoing and future clinical development efforts.